Post-market Surveillance Analysis of Refractive Data in Users of Delivery Tyro, a Tyrosine-Releasing Contact Lens.

INTRODUCTION

Myopia is a growing public health concern, particularly among young individuals. Several pharmacological and optical interventions exist to slow its progression, yet each has limitations. In January 2021, Safilens introduced the Delivery Tyro daily disposable contact lens, which releases hyaluronic acid, tamarind seed polysaccharide, and tyrosine, a dopamine precursor with antioxidative and cytoprotective properties.

METHODS

This study analyzed post-market surveillance data collected by 55 optometrists from 241 myopic subjects (mean age, 14.73 years; mean initial spherical equivalent (SE) refraction, - 2.72 diopters [D]) over a 12-month period of bilateral Delivery Tyro lens use. The purpose of the analysis was to compare the observed myopia progression in Delivery Tyro users with expected rates based on control SE refraction data derived from meta-analyses of similar age and ethnic cohorts.

RESULTS

Delivery Tyro users experienced slower rates of myopia progression than expected. After 12 months of lens wear, the average change in SE was a - 0.04 D compared with the expected change of - 0.28 D from the reference control group (P < 0.001). Furthermore, 94% of eyes exhibited no significant change in SE (defined as a change of - 0.25 D or less).

CONCLUSIONS

These findings support the hypothesis that Delivery Tyro may reduce myopia progression, likely attributable to the release of tyrosine during lens wear, either due to its antioxidative properties or its role as a precursor of dopamine, a key neurotransmitter in the retina involved in visual signaling, and refractive development. Given the convenience of daily disposable lenses, Delivery Tyro may offer a practical solution for myopia management, particularly for young patients at elevated risk of rapid myopia progression due to genetic and environmental factors. Further confirmation of the efficacy of Delivery Tyro through controlled, randomized clinical trials is warranted.